Lenvatinib/Pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors.

ABSTRACT:

SUBMITTER: Ferrucci PF 

PROVIDER: S-EPMC10170280 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature